Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

About this update from Phathom Pharmaceuticals, Inc.

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois. Phathom presented three posters at the meeting, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study that was recognized by DDW as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. Vonoprazan was also the subject of 28 additional independent, investigator-initiated abstracts across gastroesophageal reflux disease (GERD), Helicobacter pylori (H. pylori) eradication, long-term safety, and post endoscopic procedural care, reflecting the growing scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class in GI medicine. “The breadth of data presented at DDW 2026 reflects the significant scientific interest in vonoprazan across multiple acid-related conditions,” said Steve Basta, President and Chief Executive Officer of Phathom. “We are encouraged by the level of independent scientific engagement and the broad interest among researchers to evaluate vonoprazan in a range of conditions. The research highlighted at this year’s meeting adds to the growing scientific understanding of vonoprazan across multiple areas of GI medicine.” Key data presented at DDW 2026 include: Vonoprazan Abstracts Presented at DDW 2026: 28 independent abstracts reflect investigator-initiated research conducted by academic and clinical scientists across the United States, Europe, Asia, and South America: Independent Research on Vonoprazan: GERD Safety H. pylori Eradication Vonoprazan Use Post Endoscopic Submucosal Dissection Phathom-Sponsored Research on Vonoprazan: About VOQUEZNA® (vonoprazan)VOQUEZNA® (vonoprazan) tablets contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the U.S. for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, the relief of heartburn associated with Erosive GERD, the relief of...

View stock analysis, news, and events for Phathom Pharmaceuticals, Inc.